BELLICUM PHARMACEUTICALS, INC (Form: 10-Q, Received: 08/08/2016 17:04:38)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)



x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2016



o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____ to ____

Commission File Number: 001-36783

BELLICUM PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)



Delaware	2836	20-1450200
(State or other jurisdiction of incorporation or organization)	(Primary Standard Industrial Classification Code Number)	(I.R.S. Employer Identification Number)

2130 W. Holcombe Blvd., Ste. 800

Houston, TX 77030

(832) 384-1100

(Address, including zip code, and telephone number, including

area code, of registrant’s principal executive offices)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):



Large accelerated filer	o		Accelerated filer	x

Non-accelerated filer	o	(Do not check if a smaller reporting company)	Smaller reporting company	o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of July 29, 2016, there were 27,048,639 outstanding shares of Bellicum’s common stock, par value, $0.01 per share.

Table of Contents

TABLE OF CONTENTS



		Page
PART I. FINANCIAL INFORMATION		3

Item 1.	Financial Statements	3
	Balance Sheets as of June 30, 2016 (Unaudited) and December 31, 2015	3
	Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2016 and 2015 (Unaudited)	4
	Statements of Cash Flows for the six months ended June 30, 2016 and 2015 (Unaudited)	5
	Notes to Financial Statements (Unaudited)	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	14
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	23
Item 4.	Controls and Procedures	23

PART II. OTHER INFORMATION		24

Item 1.	Legal Proceedings	24
Item 1A.	Risk Factors	24
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	24
Item 6.	Exhibits	24

SIGNATURES		25

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

Bellicum Pharmaceuticals, Inc.

Balance Sheets

(In thousands, except share and par value amounts)



	June 30, 2016			December 31, 2015
	(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	49,549		$	70,241
Investment securities, available for sale - short-term	56,025			23,820
Accounts receivable, interest and other receivables	382			440
Prepaid expenses and other current assets	2,223			2,389
Total current assets	108,179			96,890
Investment securities, available for sale - long-term	30,999			56,304
Property and equipment, net	10,512			6,882
Other assets	240			330
TOTAL ASSETS	$	149,930		$	160,406
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	980		$	2,106
Accrued expenses and other current liabilities	5,367			5,080
Current portion of capital lease obligation	18			13
Current portion of deferred rent	246			246
Total current liabilities	6,611			7,445
Long-term liabilities:
Long-term debt	14,951			—
Capital lease obligation	140			118
Deferred rent and other liabilities	741			826
TOTAL LIABILITIES	22,443			8,389
Commitments and contingencies: (Note: 9)
Stockholders’ equity:
Preferred stock: $0.01 par value; 10,000,000 shares authorized: no shares issued and outstanding	—			—
Common stock, $0.01 par value; 200,000,000 shares authorized at June 30, 2016 and December 31, 2015, 27,720,406 shares issued and 27,042,943 shares outstanding at June 30, 2016; 27,609,344 shares issued and 26,931,881 shares outstanding at December 31, 2015	277			276
Treasury stock: 677,463 shares held at June 30, 2016 and December 31, 2015	(5,056		)	(5,056		)
Additional paid-in capital	325,246			318,591
Accumulated other comprehensive income (loss)	96			(302		)
Accumulated deficit	(193,076		)	(161,492		)
Total stockholders’ equity	127,487			152,017
Total liabilities and stockholders’ equity	$	149,930		$	160,406

See accompanying notes, which are an integral part of these unaudited financial statements.

Table of Contents

Bellicum Pharmaceuticals, Inc.

Statements of Operations and Comprehensive Income (Loss)

(In thousands, except share and per share amounts)

(Unaudited)



	Three months ended June 30,						Six months ended June 30,
	2016			2015			2016			2015
REVENUES
Grants	$	101		$	84		$	193		$	191
Total revenues	101			84			193			191
OPERATING EXPENSES
Research and development	12,181			8,012			23,169			13,730
General and administrative	4,179			2,777			8,463			4,974
Total operating expenses	16,360			10,789			31,632			18,704
Loss from operations	(16,259		)	(10,705		)	(31,439		)	(18,513		)
OTHER INCOME (EXPENSE):
Interest income	236			171			463			221
Interest expense	(486		)	—			(608		)	—
Total other income (expense)	(250		)	171			(145		)	221
NET LOSS	$	(16,509	)	$	(10,534	)	$	(31,584	)	$	(18,292	)

Net loss per common share attributable to common shareholders, basic and diluted	$	(0.61	)	$	(0.40	)	$	(1.17	)	$	(0.70	)
Weighted-average shares outstanding, basic and diluted	26,910,284			26,268,610			26,896,405			26,264,025

Net loss	$	(16,509	)	$	(10,534	)	$	(31,584	)	$	(18,292	)
Other comprehensive income (loss):
Unrealized gain (loss) on investment securities	152			(204		)	398			(204		)
Comprehensive loss	$	(16,357	)	$	(10,738	)	$	(31,186	)	$	(18,496	)

See accompanying notes, which are an integral part of these unaudited financial statements.

Table of Contents

Bellicum Pharmaceuticals, Inc.

Statements of Cash Flows

(In thousands)

(Unaudited)



	Six months ended June 30,
	2016			2015
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(31,584	)	$	(18,292	)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	6,183			3,636
Depreciation expense	951			375
Amortization of premium on investment securities, net	340			169
Amortization of lease liability	(85		)	(22		)
Amortization of deferred financing costs	150			—
Loss on disposition of fixed assets	20			—
Changes in operating assets and liabilities:
Receivables	58			(164		)
Prepaid expenses and other assets	256			(945		)
Accounts payable	(1,126		)	(395		)
Accrued liabilities and other	287			(513		)
NET CASH USED IN OPERATING ACTIVITIES	(24,550		)	(16,151		)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of investment securities	(22,700		)	(73,619		)
Proceeds from sale of investment securities	15,858			2,327
Purchases of property and equipment	(4,567		)	(2,746		)
CASH USED IN INVESTING ACTIVITIES	(11,409		)	(74,038		)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of common stock - ESPP	188			159
Proceeds from exercise of stock options	285			82
Proceeds from notes payable	15,000			—
Payment of debt issuance costs	(199		)	—
Payment of issuance costs on common stock	—			(8		)
Payment on capital lease obligation	(7		)	—
NET CASH PROVIDED BY FINANCING ACTIVITIES	15,267			233
NET CHANGE IN CASH AND CASH EQUIVALENTS	(20,692		)	(89,956		)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	70,241			191,602
CASH AND CASH EQUIVALENTS AT END OF PERIOD	$	49,549		$	101,646
SUPPLEMENTAL CASH FLOW INFORMATION:
Interest paid	$	342		$	—

NON-CASH INVESTING AND FINANCING ACTIVITIES
Capital lease obligation incurred for property and equipment	$	34		$	—
Purchases of property and equipment in accounts payables and accrued liabilities	$	1,119		$	—
Accrued issuance costs for long-term debt	$	1,216		$	—

See accompanying notes, which are an integral part of these unaudited financial statements.

Table of Contents

Bellicum Pharmaceuticals, Inc.

Notes to Unaudited Financial Statements

NOTE 1 - ORGANIZATION AND BUSINESS DESCRIPTION

Bellicum Pharmaceuticals, Inc., the Company or Bellicum, was incorporated in Delaware in July 2004 and is based in Houston, Texas. The Company is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is devoting substantially all of its present efforts to developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including, hematopoietic stem cell transplantation, CAR T and TCR cell therapy. The Company has not generated any revenue from product sales to date and does not anticipate generating revenues from product sales in the foreseeable future.

The Company is subject to risks common to companies in the biotechnology industry and the future success of the Company is dependent on its ability to successfully complete the development of, and obtain regulatory approval for, its product candidates, manage the growth of the organization, obtain additional financing necessary in order to develop, launch and commercialize its product candidates, and compete successfully with other companies in its industry.

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying interim financial statements are unaudited. These unaudited interim financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and following the requirements of the U.S. Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP have been omitted. In management’s opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position and its results of operations and its cash flows for the periods presented. These statements do not include all disclosures required by GAAP and should be read in conjunction with the Company’s Annual Report on Form 10-K filed for the fiscal year ended December 31, 2015 (the Annual Report). A copy of the Annual Report is available on the SEC’s website, www.sec.gov , under the Company’s ticker symbol “BLCM” or on Bellicum’s website, www.bellicum.com . The results for the interim periods are not necessarily indicative of the results expected for the full fiscal year or any other interim period. Any reference in these footnotes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB).

Use of Estimates

The preparation of the financial statements in accordance with GAAP requires management to make certain estimates and judgments that affect the reported amounts of assets, liabilities, and expenses. Actual results could differ from those estimates.

Net Loss and Net Loss per Share of Common Stock Attributable to Common Stockholders

Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period without consideration for common stock equivalents. Diluted net loss per share of common stock is the same as basic net loss per share of common stock, since the effects of potentially dilutive securities are antidilutive. The following outstanding shares of common stock equivalents were excluded from the computations of diluted net loss per shares of common stock attributable to common stockholders for the periods presented, as the effect of including such securities would be anti-dilutive.



	As of June 30,
Common Stock Equivalents:	2016	2015
	Number of shares
Warrants to purchase common stock	—	355,392
Unvested shares of restricted stock	88,236	117,647
Options to purchase common stock	4,518,961	3,541,577
	4,607,197	4,014,616

Table of Contents

Investment Securities

Consistent with its investment policy, the Company invests its cash allocated to fund its short-term liquidity requirements with prominent financial institutions in bank depository accounts and institutional money market funds and the Company invests the remainder of its cash in corporate debt securities and municipal bonds rated at least A quality or equivalent, U.S. Treasury notes and bonds and U.S. and state government agency-backed securities.

The Company determines the appropriate classification of investment securities at the time of purchase and reevaluates its classification as of each balance sheet date. All investment securities owned during the six months ended June 30, 2016, were classified as available-for-sale. The cost of securities sold is based on the specific identification method. Investment securities are recorded as of each balance sheet date at fair value, with unrealized gains and, to the extent deemed temporary, unrealized losses included in stockholders’ equity. Interest and dividend income on investment securities, accretion of discounts and amortization of premiums and realized gains and losses are included in interest income in the Statements of Operations and Comprehensive Income Loss.

An investment security is considered to be impaired when a decline in fair value below its cost basis is determined to be other than temporary. The Company evaluates whether a decline in fair value of an investment security is below its cost basis and is other than temporary using available evidence. In the event that the cost basis of the investment security exceeds its fair value, the Company evaluates, among other factors, the amount and duration of the period that the fair value is less than the cost basis, the financial health of and business outlook for the issuer, including industry and sector performance, and operational and financing cash flow factors, overall market conditions and trends, the Company’s intent to sell the investment security and whether it is more likely than not the Company would be required to sell the investment security before its anticipated recovery. If a decline in fair value is determined to be other than temporary, the Company records an impairment charge in the statement of comprehensive income (loss) and establishes a new cost basis in the investment.

Debt Issuance Costs

Costs related to debt issuance are presented in the balance sheet as a direct deduction from the carrying amount of the debt liability, consistent with debt discounts.

Recently Issued Accounting Pronouncements

In April 2015, the FASB issued ASU No. 2015-03, “Simplifying the Presentation of Debt Issuance Costs . ” ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. In the first quarter of 2016, the Company adopted ASU No. 2015-03.

In February 2016, the FASB issued ASU No. 2016-02, “Leases” ASU 2016-01 requires companies that lease assets to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments, in its balance sheet. The pronouncement will also require additional disclosures about the amount, timing and uncertainty of cash flows arising from leases. This pronouncement is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018, and early adoption is permitted. Management is currently evaluating the impact of this pronouncement on the Company’s statements.

In March 2016, the FASB issued ASU No. 2016-09, “Compensation-Stock Compensation.” ASU 2016-09 simplifies accounting for share-based compensation arrangements, primarily as it relates to accounting for the income tax effects of share-based compensation. Under the pronouncement, an entity can make an entity-wide accounting policy decision to either estimate the number of awards that are expected to vest (current GAAP) or account for forfeitures as they occur. The pronouncement is effective for annual periods beginning after December 31, 2016, and interim periods within those annual periods. Earlier application is permitted in any interim or annual period. The Company does not believe the adoption of this standard will have a material impact on the Company's financial statements.

In June 2016, the FASB issued ASU 2016-13, “ Measurement of Credit Losses on Financial Instruments ”, which replaces the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The new standard is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years with early adoption permitted in fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Management is currently evaluating the impact of this pronouncement on the Company’s statements.

The Company has evaluated other recent accounting pronouncements and believes that none of them will have a material effect on the Company’s financial statements.

Table of Contents

NOTE 3 - FAI R VALU E MEASUREMENTS AND INVESTMENT SECURITIES

Fair Value Measurement

The Company follows ASC, Topic 820, Fair Value Measurements and Disclosures , or ASC 820, for application to financial assets. ASC 820 defines fair value, provides a consistent framework for measuring fair value under GAAP and requires fair value financial statement disclosures. ASC 820 applies only to the measurement and disclosure of financial assets that are required or permitted to be measured and reported at fair value under other ASC topics (except for standards that relate to share-based payments such as ASC Topic 718, Compensation – Stock Compensation ).

The valuation techniques required by ASC 820 may be based on either observable or unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, and unobservable inputs reflect the Company’s market assumptions.

These inputs are classified into the following hierarchy:

Level 1 Inputs – quoted prices (unadjusted) in active markets for identical assets that the reporting entity has the ability to access at the measurement date;

Level 2 Inputs – inputs other than quoted prices included within Level 1 that are observable for the asset, either directly or indirectly; and

Level 3 Inputs – unobservable inputs for the assets.

The following tables present the Company’s investment securities (including, if applicable, those classified on the Company’s balance sheet as cash equivalents) that are measured at fair value on a recurring basis as of June 30, 2016 and December 31, 2015 , respectively:



			Fair Value Measurements at Reporting Date
	Balance at June 30, 2016		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
	(in thousands)
Cash Equivalents:
Money market funds	$	35,472	$	35,472	$	—	$	—
Corporate debt securities	2,900		—		2,900		—
Total Cash Equivalents	$	38,372	$	35,472	$	2,900	$	—

Investment Securities:
U.S. government agency-backed securities	$	33,983	$	—	$	33,983	$	—
Corporate debt securities	48,882		—		48,882		—
Municipal bonds	4,159		—		4,159		—
Total Investment Securities	$	87,024	$	—	$	87,024	$	—

Table of Contents



			Fair Value Measurements at Reporting Date
	Balance at December 31, 2015		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
	(in thousands)
Cash Equivalents:
Money market funds	$	52,714	$	52,714	$	—	$	—
U.S. government agency-backed securities	9,500		—		9,500		—
Total Cash Equivalents	$	62,214	$	52,714	$	9,500	$	—

Investment Securities:
U.S. government agency-backed securities	$	22,388	$	—	$	22,388	$	—
Corporate debt securities	51,547		—		51,547		—
Municipal bonds	6,189		—		6,189		—
Total Investment Securities	$	80,124	$	—	$	80,124	$	—

Corporate debt securities and municipal bonds are valued based on various observable inputs such as benchmark yields, reported trades, broker/dealer quotes, benchmark securities and bids.

Investment securities, all classified as available-for-sale, consisted of the following as of June 30, 2016 :



	June 30, 2016
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Aggregate Estimated Fair Value
	(in thousands)
Investment Securities:
U.S. government agency-backed securities	$	33,956	$	31	$	(4	)	$	33,983
Corporate debt securities	48,816		101		(35		)	48,882
Municipal bonds	4,156		4		(1		)	4,159
Total Investment Securities	$	86,928	$	136	$	(40	)	$	87,024

The Company's investment securities as of June 30, 2016 , will reach maturity between July 2016 and January 2019 , with a weighted-average maturity date in May 2017 .

Management believes that the carrying value of the debt facility approximates its fair value, as the Company's debt facility bears interest at a rate that approximates prevailing market rates for instruments with similar characteristics. The fair value of the Company's debt facility is determined under Level 2 in the fair value hierarchy.

Table of Contents

NOTE 4 – ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Accrued liabilities and other liabilities consist of the following:



	June 30, 2016		December 31, 2015
	(in thousands)
Accrued manufacturing costs	$	1,585	$	2,412
Accrued payroll	896		1,332
Accrued property and equipment purchases	943		139
Accrued patient treatment costs	296		333
Accrued medical facility fees	159		282
Accrued other	1,488		582
Total accrued expenses and other current liabilities	$	5,367	$	5,080

NOTE 5 - DEBT

On March 10, 2016 (the Closing Date), the Company, entered into a Loan and Security Agreement (the Loan Agreement) with Hercules Capital, Inc. (Hercules), as agent and a lender, Hercules Technology II, L.P., as a lender, and Hercules Technology III, L.P., as a lender, under which the Company borrowed $15.0 million on the Closing Date and may borrow an additional $5.0 million on or prior to September 15, 2016. Subject to the terms and conditions of the Loan Agreement, including approval by Hercules’ investment committee and the Company’s achievement of specified milestones in the Loan Agreement (the Milestones), the Company may borrow an additional $10.0 million through March 15, 2017. The Company intends to use the proceeds received under the Loan Agreement for funding the build-out of our manufacturing facilities and general corporate purposes.

The interest rate will be calculated at a rate equal to the greater of either (i) 9.35% plus the prime rate as reported in The Wall Street Journal minus 3.50% , and (ii) 9.35% . Payments under the Loan Agreement are interest only for 18 months from the Closing Date, extendable to 24 months upon the Company achieving the Milestones. The interest only period will be followed by equal monthly payments of principal and interest amortized over a 30 months schedule through the maturity date of March 1, 2020 (the “Loan Maturity Date”); provided that if the Milestones are achieved, the Company will make equal monthly payments of principal and interest amortized over a 24 months schedule through the Loan Maturity Date. The remaining principal balance will be due and payable on the Loan Maturity Date. In addition, upon the Loan Maturity date or such earlier date specified in the Loan Agreement, a final payment equal to $1,216,250 (the Final Facility Charge), plus, subject to and contingent on the funding of the additional $5.0 million loan advance, $173,750 ; plus, subject to and contingent on the funding of the additional $10.0 million loan advance, $695,000 . The Company’s obligations under the Loan Agreement are secured by a security interest in substantially all of its assets, other than its intellectual property.

If the Company prepays the loan, including interest, prior to December 31, 2016, there will be no prepayment penalty. If the Company prepays the loan, including interest, after January 1, 2017 but prior to the date that is 24 months following the Closing Date, it will pay Hercules a prepayment charge based on a prepayment fee equal to 2.00% of the amount prepaid; if the prepayment occurs thereafter, it will pay Hercules a prepayment charge based on a prepayment fee equal to 1.00% of the amount prepaid. The prepayment charge is also applicable upon the occurrence of a change of control of the Company. In addition to a prepayment charge, if any, the Company will pay Hercules the Final Facility Charge.

The Loan Agreement includes customary affirmative and restrictive covenants, but does not include any financial maintenance covenants, and also includes standard events of default, including payment defaults. Upon the occurrence of an event of default, a default interest rate of an additional 5% may be applied to the outstanding loan balance and Hercules may declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement.

The Company paid expenses related to the Loan Agreement of $199,000 , which, alo ng with the Final Facility Charge of $1,216,250 , have been recorded as deferred financing costs, which offset long-term debt on the Company's balance sheet. Deferred financing costs of $1,415,250 will be amortized over the term of the loan, and included in interest expense. During the three and six months ended June 30, 2016, interest expense included $122,000 and $150,000 , respectively, of amortized deferred financing costs.

Table of Contents

NOTE 6 - SHARE-BASED COMPENSATION

At June 30, 2016 , the Company had share-based awards outstanding under four share-based compensation plans as follows:

The 2006 Stock Option Plan (the 2006 Plan) provided for the issuance of non-qualified stock options to employees, including officers, non-employee directors and consultants to the Company. As of June 30, 2016, 151,410 shares of common stock were reserved for issuance pursuant to outstanding options previously granted under the 2006 Plan to purchase common stock of the Company. The 2006 Plan was terminated by the Board in October 2014.

The 2011 Stock Option Plan (the 2011 Plan) provided for the issuance of incentive and non-qualified stock options to employees, including officers, non-employee directors and consultants to the Company. As of June 30, 2016, 2,141,616 shares of common stock were reserved for issuance pursuant to outstanding options previously granted under the 2011 Plan to purchase common stock of the Company. The 2011 Plan terminated upon the effectiveness of the 2014 Plan described below.

The 2014 Equity Incentive Plan (the 2014 Plan) became effective in December 2014, upon the closing of the Company's initial public offering. The 2014 Plan provides for the issuance of equity awards, including incentive and non-qualified stock options and restricted stock awards to employees, including officers, non-employee directors and consultants to the Company or its affiliates. The 2014 Plan also provides for the grant of performance cash awards and performance-based stock awards. The aggregate number of shares of common stock that are authorized for issuance under the 2014 Plan is 2,990,354 shares, plus any shares subject to outstanding options that were granted under the 2011 Plan or 2006 Plan that are forfeited, terminated, expired or are otherwise not issued.

The 2014 Employee Stock Purchase Plan (the ESPP) provides for eligible Company employees, as defined by the ESPP, to be given an opportunity to purchase our common stock at a discount, through payroll deductions, with stock purchases being made upon defined purchase dates. The ESPP authorizes the issuance of up to 550,000 shares of our common stock, pursuant to purchase rights granted to our employees. During the six months ended June 30, 2016, 17,115 shares were purchased under the ESPP and the company received $0.2 million in proceeds.



A summary of activity within the ESPP follows:	Six months ended June 30,
	2016		2015
	(in thousands)
Deductions from employees	$	188	$	159
Share-based compensation expense recognized	$	133	$	109
Remaining share-based compensation expense	$	134	$	300

The Company granted options to purchase 145,333 and 1,040,457 shares of its common stock during the three and six months ended June 30, 2016. The fair value of the option grants during the six months ended June 30, 2016 and 2015 was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions:



	Six months ended June 30,
	2016		2015
Expected volatility	72.0	%	91.2	%
Expected term (in years)	6.08		6.08
Risk-free interest rate	1.81	%	1.60	%
Expected dividend yield	—	%	—	%

At June 30, 2016 , there was $32.0 million of unrecognized compensation expense related to unvested stock options and stock that is expected to be recognized over a weighted-average period of 2.8 years.

During the three and six months ended June 30, 2016, the Company received cash proceeds from the exercise of stock options of approximately $0.2 million and $0.3 million , respectively. The aggregate intrinsic value of options exercised during the three and six months ended June 30, 2016 was $0.4 million and $1.1 million , respectively.

Share-based compensation for the three and six months ended June 30, 2016 and 2015 are as follows:

Table of Contents



	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2015		2016		2015
	(in thousands)				(in thousands)
General and administrative	$	1,374	$	962	$	2,760	$	1,561
Research and development	1,744		1,186		3,423		2,075
Total	$	3,118	$	2,148	$	6,183	$	3,636

The following table summarizes the stock option activity for all stock plans during the six months ended June 30, 2016:



	Options		Weighted- Average Exercise Price Per Share		(in years) Weighted- Average Contractual Life	(in thousands) Aggregate Intrinsic Value ⁽¹⁾
Outstanding at December 31, 2015	3,628,973		$	10.32	8.03	$	39,021
Granted	1,040,457		$	17.49
Exercised	(93,947	)	$	3.04
Canceled or forfeited	(56,522	)	$	12.39
Outstanding at June 30, 2016	4,518,961		$	12.10	8.01	$	19,699
Exercisable at June 30, 2016	2,042,365		$	7.01	6.83	$	15,798

⁽¹⁾ The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money at June 30, 2016.

At June 30, 2016 and December 31, 2015, there were 88,236 shares of unvested common stock outstanding.

NOTE 7 - GRANT REVENUE

NIH Grant

During both 2015 and 2016, the Company was awarded $0.3 million , under grants from the National Institutes of Health (NIH). The awards cover the period from April 2015 through March 2017. The awards were made pursuant to the authority of 42 USC 241 42 CFR 52, and are subject to the requirements of the statute. Funds spent on the grant are reimbursed through monthly reimbursement requests. Funds spent under the grant were approximately $0.1 million and $0.2 million during the three and six month periods ended June 30, 2016, respectively. As of June 30, 2016 and December 31, 2015, the Company had a receivable of $5,400 and $57,000 , respectively, pursuant to the grants.

NOTE 8 - LICENSE AGREEMENTS

License Agreements - Baylor

In March 2016, the Company and Baylor College of Medicine ( “ BCM ” ) entered into two additional license agreements pursuant to which the Company obtained exclusive rights to technologies and patent rights owned by BCM. The Company paid BCM a non-refundable license fee of $0.1 million , and could incur additional payments upon the achievement of certain milestone events as set forth in the agreement. If the Company is successful in developing any of the licensed technologies, resulting sales would be subject to a royalty payment in the low single digits.

License Agreements - Leiden

In May 2016, the Company and Academisch Ziekenhuis Leiden (“Leiden”) entered into a research collaboration agreement pursuant to which the Company will provide Leiden with financial support for research to discover and validate high-affinity TCR product candidates targeting several cancer-associated antigens.

The Company agreed to pay Leiden an aggregate of EURO 2,547,415 in quarterly installments during the three-year term of the research, which will be recognized as services are incurred. During the three and six months ended June 30, 2016, $0.1 million of

Table of Contents

research services were recognized. With respect to any inventions arising from the research that are relevant to or useful for any high affinity TCR that is studied in the research, Leiden granted the Company an exclusive option to obtain an exclusive, worldwide license to practice and exploit such inventions. The parties agreed to negotiate in good faith the commercially reasonable terms of each such license agreement entered into between the parties, based on terms similar to those set forth in the previously executed license agreement between the parties and those specified in the agreement.

NOTE 9 - COMMITMENTS AND CONTINGENCIES

Litigation

The Company, from time to time, may be involved in litigation relating to claims arising out of its ordinary course of business. Management believes that there are no material claims or actions pending or threatened against the Company.

NOTE 10 - SUBSEQUENT EVENTS

On July 11, 2016, the Company entered into a First Amendment to Lease Agreement (the “Lease Amendment”) with Life Science Plaza Investment Group, LP, as successor-in-interest to Sheridan Hills Developments, L.P. (the “Original Landlord”) to amend the Lease Agreement, dated May 6, 2015, between the Company and the Original Landlord (the “Lease”). Pursuant to the Lease Amendment, the initial term of the Lease was extended to August 31, 2026 and the Company leased an aggregate of 3,328 additional square feet (the “Expansion Space”). For the Expansion Space, the Company is required to remit base monthly rent of approximately $5,800 , which will increase at an average approximate rate of 5% per year.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2015, or our Annual Report, as well as our unaudited financial statements and related notes included in this Quarterly Report on Form 10-Q, or this Quarterly Report.

Forward-Looking Statements

This report contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the “safe harbor” created by those sections. These forward-looking statements include, but are not limited to, statements concerning our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management. The words “anticipate,” “believe,” “could,” “designed,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “project," “will," “would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks set forth in Part I, Item 1A, “Risk Factors” in our Annual Report and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements.

Overview

We are a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors, as well as orphan inherited blood disorders. We are using our proprietary Chemical Induction of Dimerization, or CID, technology platform to engineer our product candidates with switch technologies that can control components of the immune system in real time. By incorporating our CID platform, our product candidates may offer better safety and efficacy outcomes than are seen with current cellular immunotherapies.

We are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation, or HSCT, chimeric antigen receptor T cell therapy, or CAR Ts, and T cell receptors, or TCRs. HSCT, also known as bone marrow transplantation, has for decades been curative for many patients with hematological cancers or orphan inherited blood disorders. However, adoption of HSCT to date has been limited by the risks of transplant-related morbidity and mortality from graft-versus-host-disease, or GvHD, and the potential for serious infections due to the lack of an effective immune system following a transplant. CAR T and TCR cell therapies are an innovative approach in which a patient’s T cells are genetically modified to carry chimeric antigen receptors, or CARs, or TCRs which redirect the T cells against cancer cells. While high objective response rates have been reported in some hematological malignancies, serious and sometimes fatal toxicities have arisen in patients treated with CAR T cell therapies. These toxicities include instances in which the CAR T cells have caused high levels of cytokines due to over-activation, referred to as “cytokine release syndrome”, neurologic toxicities and cases in which they have attacked healthy organs. In each case, these toxicities have sometimes resulted in death. In solid tumors, where the behavior of CAR T cells is particularly unpredictable and results have been inconsistent, researchers are developing enhanced CAR T cell approaches called “armored CARs” that raise even greater safety concerns.

Our proprietary CID platform is designed to address these challenges. Events inside a cell are controlled by cascades of specialized signaling proteins. CID consists of molecular switches, modified forms of these signaling proteins, which are triggered inside the patient by infusion of a small molecule, rimiducid, instead of by natural upstream signals. We include these molecular switches in the appropriate immune cells and deliver the cells to the patient in the manner of conventional cellular immunotherapy. We have developed two such switches: a “safety switch,” designed to initiate programmed cell death, or apoptosis, of the immunotherapy cells, and an “activation switch,” designed to stimulate activation and in some cases proliferation and/or persistence of the immunotherapy cells. Each of our product candidates incorporates one of these switches, for enhanced, real time control of safety and efficacy:


•	CaspaCIDe is our safety switch, incorporated into our HSCT, and in certain of our TCR, product candidates, where it is inactive unless the patient experiences a serious side effect. In that event, rimiducid is administe

Table of Contents

red to fully or partially eliminate the cells, with the goal of terminating or attenuating the therapy and resolving the serious side effect.

•

Our “Go” switch incorporated into our GoCAR T product candidates is designed to allow control of the activation and proliferation of the T cells through the scheduled administration of a course of rimiducid infusions that may continue until the desired patient outcome is achieved. In the event of emergence of side effects, the level of activation of the GoCAR T cells is designed to be attenuated by extending the interval between rimiducid doses, reducing the dosage per infusion, or suspending further rimiducid administration.

By incorporating our novel switch technologies, we are developing product candidates with the potential to elicit positive clinical outcomes and ultimately change the treatment paradigm in various areas of cellular immunotherapy. Our lead clinical product candidate is described below.

•

BPX-501. We are developing a CaspaCIDe product candidate, BPX-501, as an adjunct T cell therapy administered after allogeneic HSCT. BPX-501 is designed to improve transplant outcomes by enhancing the recovery of the immune system following an HSCT procedure. BPX-501 addresses the risk of infusing donor T cells by enabling the elimination of donor T cells through the activation of the CaspaCIDe safety switch if there is an emergence of uncontrolled GvHD.

In addition, our preclinical product candidates are designed to overcome the current limitations of CAR T and TCR therapies and include the following:

•

BPX-701 is a CaspaCIDe-enabled natural high affinity T cell receptor, or TCR, product candidate designed to target malignant cells expressing the preferentially-expressed antigen in melanoma, or PRAME. Initial planned indications for BPX-701 development are Refractory or Relapsed Acute Myeloid Leukemia, or AML, and Myelodysplastic Syndromes, or MDS, with an additional study planned for metastatic uveal melanoma. Each of these is an orphan indication where PRAME is highly expressed and for which current treatment options are limited.

•

BPX-601 is a GoCAR T product candidate containing our proprietary iMC, inducible MyD88/CD40, activation switch, designed to treat solid tumors expressing prostate stem cell antigen, or PSCA. Preclinical data shows enhanced T cell proliferation, persistence and in vivo anti-tumor activity compared to traditional CAR T therapies. The initial planned indication for BPX-601 development is non-resectable pancreatic cancer.

On January 11, 2016, we submitted required documentation, for our two most advanced CAR T and TCR adoptive cell therapy product candidates, BPX-601 and BPX-701, for review by the National Institutes of Health, or NIH, Recombinant DNA Advisory Committee (RAC). Public review of those programs occurred at the RAC Meeting on March 9, 2016.

We filed Investigational New Drug Applications, or INDs, for BPX-601 and BPX-701, in the second quarter of 2016. Both INDs have been allowed and we are in final preparation for these product candidates to begin clinical studies.

We have developed an efficient and scalable process to manufacture genetically modified T cells of high quality, which is currently being used by our third-party contract manufacturers to produce BPX-501 for our clinical trials. We are leveraging this process, as well as our resources, capabilities and expertise for the manufacture of our CAR T and TCR product candidates.

Recent Developments

On July 11, 2016, we entered into a first amendment to our lease agreement with Life Science Plaza Investment Group, LP, as successor-in-interest to Sheridan Hills Developments, L.P., or the Original Landlord, to amend the Lease Agreement, dated May 6, 2015, between the Original Landlord and us. Pursuant to the first amendment, the initial term of the lease was extended to August 31, 2026 and we leased an aggregate of 3,328 additional square feet, or the “Expansion Space”. For the expansion space, we are required to remit base monthly rent of approximately $5,800, which will increase at an average approximate rate of 5% per year. See Note 10.

In July 2016, the Company decided to support CD19 programs designed to establish clinical proof of concept for CaspaCIDe in the CD19 setting being advanced by two of our academic collaborators, in place of advancing BPX-401. The Company believes

Table of Contents

that this strategy allows a cost-effective and differentiated approach to the highly competitive landscape of CD19-targeted therapies in development.

Critical Accounting Policies and Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires us to make judgments, estimates and assumptions in the preparation of our financial statements and accompanying notes. Actual results could differ from those estimates. We believe there have been no material changes in our critical accounting policies as discussed in our Annual Report.

Table of Contents

Financial Operations Overview

Revenues

To date, we have only recognized revenue from government grants and we have not generated any product revenue. We have received funds from the National Institutes of Health, or NIH, which was awarded based on the progress of the program being funded. In cases when the grant money is not received until expenses for the program are incurred, we accrue the revenue based on the costs incurred for the programs associated with the grant.

During 2013, we entered into a grant agreement with the NIH. The grant is a modular five year grant with funds being awarded each year based on the progress of the program being funded. Grant money is not received until expenses for the program are incurred. We have been awarded approximately $1.3 million to date, of which $1.0 million has been received. We accrue the revenue based on the costs incurred for the programs associated with the grant.

In the future, we may generate revenue from a combination of product sales, government or other third-party grants, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or a combination of these approaches. We expect that any revenue we generate will fluctuate from quarter to quarter as a result of the timing and amount of license fees, milestone and other payments, and the amount and timing of payments that we receive upon the sale of our products, to the extent any are successfully commercialized. If we fail to complete the development of our product candidates in a timely manner or obtain regulatory approval of them, our ability to generate future revenue, and our results of operations and financial position, would be materially adversely affected.

Research and Development Expenses

To date, our research and development expenses have related primarily to the development of our CID platform and the identification and development of our product candidates. Research and development expenses consist of expenses incurred in performing research and development activities, including compensation and benefits for research and development employees and consultants, facilities expenses, overhead expenses, cost of laboratory supplies, manufacturing expenses, fees paid to third parties and other outside expenses.

Research and development costs are expensed as incurred. Clinical trial and other development costs incurred by third parties are expensed as the contracted work is performed. We accrue for costs incurred as the services are being provided by monitoring the status of the clinical trial or project and the invoices received from our external service providers. We adjust our accrual as actual costs become known. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone events are achieved.

We utilize our research and development personnel and infrastructure resources across several programs, and many of our costs are not specifically attributable to a single program. Accordingly, we cannot state precisely our total costs incurred on a program-by-program basis.

Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development expenses to increase over the next several years as we seek to conduct our ongoing and planned clinical trials for BPX-501, BPX-601 and BPX-701 and as we selectively develop additional product candidates. However, it is difficult to determine with certainty the duration and completion costs of our current or future preclinical programs and clinical trials of our product candidates.

The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors that include, but are not limited to, the following:


•	per patient clinical trial costs;


•	the number of patients that participate in the clinical trials;


•	the number of sites included in the clinical trials;


•	the process of collection, differentiation, selection and expansion of immune cells for our cellular immuno-therapies;


•	the countries in which the clinical trials are conducted;

Table of Contents


•	the outcomes of our clinical trials;


•	the length of time required to enroll eligible patients;


•	the number of doses that patients receive;


•	the drop-out or discontinuation rates of patients;


•	potential additional safety monitoring or other studies requested by regulatory agencies;


•	the duration of patient follow-up; and


•	the efficacy and safety profile of the product candidates.

In addition, the probability of success for each product candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the ongoing scientific and clinical success of each product candidate, as well as an assessment of each product candidate’s commercial potential.

General and administrative expenses

General and administrative expenses consist primarily of salaries and other related costs, including share-based compensation, for personnel in executive, finance, accounting, business and commercial development, legal and human resources functions. Other significant costs include facility costs not otherwise included in research and development expenses, legal fees relating to corporate matters, insurance costs and professional fees for consultancy, legal, accounting, audit and investor relations.

We anticipate that our general and administrative expenses will increase in the future to support our growth, expanding research and development activities, potential commercialization of our product candidates and costs of operating as a public company. These increases will likely include increased costs related to the hiring of additional personnel, facilities and fees to outside consultants, lawyers and accountants, among other expenses.

Income Taxes

We did not recognize any income tax expense for the three and six months ended June 30, 2016 or 2015.

Results of Operations

Comparison of the Three and Six Months Ended June 30, 2016 and 2015

The following table sets forth our results of operations for the three and six months ended June 30, 2016 and 2015:



	Three Months Ended June 30,									Six Months Ended June 30,
	2016			2015			Change			2016			2015			Change
	(in thousands)									(in thousands)
Grant revenues	$	101		$	84		$	17		$	193		$	191		$	2
Operating expenses:
Research and development	12,181			8,012			4,169			23,169			13,730			9,439
General and administrative	4,179			2,777			1,402			8,463			4,974			3,489
Total operating expenses	16,360			10,789			5,571			31,632			18,704			12,928
Loss from operations	(16,259		)	(10,705		)	(5,554		)	(31,439		)	(18,513		)	(12,926		)
Other income (expense):
Interest income	236			171			65			463			221			242
Interest expense	(486		)	—			(486		)	(608		)	—			(608		)
Total other income (expense)	(250		)	171			(421		)	(145		)	221			(366		)
Net loss	$	(16,509	)	$	(10,534	)	$	(5,975	)	$	(31,584	)	$	(18,292	)	$	(13,292	)

Table of Contents

Research and Development Expenses

Research and development expenses were $12.2 million and $8.0 million for the three months ended June 30, 2016 and June 30, 2015, respectively. The $4.2 million increase in research and development expenses for the three months ended June 30, 2016, was due to an increase in clinical and manufacturing costs of $4.5 million related to BPX-501, primarily due to increased patient enrollment in our clinical trials. The higher research and development expenses were also due to an increase of $0.9 million for IND enabling activities on our product candidates, BPX-601 and BPX-701, partially offset by a decrease of $1.2 million in general research and development costs, primarily due to a change order agreed to with a service provider that reduced our work commitment and financial obligations.

Research and development expenses were $23.2 million and $13.7 million for the six months ended June 30, 2016 and 2015, respectively. The $9.4 million increase in research and development expenses for the six months ended June 30, 2016, was due to an increase in clinical and manufacturing costs of $6.9 million related to BPX -501, primarily due to increased patient enrollment in our clinical trials. The increase in research and development expenses is also due to an increase of $1.7 million related to IND enabling activities on BPX-601; plus an increase of $0.8 million in general research and development costs which includes personnel costs and allocated overhead costs.

The following table presents our research and development expense by project/category for the periods indicated:



	Three Months Ended June 30,							Six Months Ended June 30,
Product Candidates	2016		2015		Change			2016		2015		Change
	(in thousands)							(in thousands)
BPX-501	$	7,447	$	2,899	$	4,548		$	12,505	$	5,645	$	6,860
BPX-601	1,310		167		1,143			1,899		192		1,707
BPX-701	68		339		(271		)	280		358		(78		)
General	3,356		4,607		(1,251		)	8,485		7,535		950
Total	$	12,181	$	8,012	$	4,169		$	23,169	$	13,730	$	9,439

General and Administrative Expenses

General and administrative, or G&A, expenses were $4.2 million and $8.4 million for the three and six months ended June 30, 2016, respectively, and $2.8 million and $5.0 million for the three and six months ended June 31, 2015, respectively. The increase in G&A expenses of $1.4 million and $3.5 million for the three and six months ended June 30, 2016, respectively, was primarily due to our overall growth, including an increase in costs related to personnel, higher facility costs and increased legal, accounting and travel expenses.

Liquidity and Capital Resources

Sources of Liquidity

We are a clinical stage biopharmaceutical company with a limited operating history. To date, we have financed our operations primarily through equity and debt financings and grants. We have not generated any revenue from the sale of any products. As of June 30, 2016 and December 31, 2015, we had cash, cash equivalents and investment securities of $136.6 million and $150.4 million , respectively. Cash in excess of near term requirements is invested in accordance with our investment policy, primarily with a view to liquidity and capital preservation.

On March 10, 2016, we entered into a term loan arrangement with Hercules Capital, Inc. as agent and lender, and borrowed $15.0 million on the closing date. We have the ability to borrow another $5.0 million on or prior to September 15, 2016, and, subject to the achievement of specified milestones in the loan agreements and approval by Hercules' investment committee, may borrow another $10 million through March 15, 2017. We intend to use the proceeds to fund the build-out of our manufacturing facilities, and for general corporate purposes.

We are required to make monthly interest only payments through September 2017. The interest only feature can be extended for an additional six months if we achieve specified milestones. After the expiration of the interest only period, we are required to repay the loan over the remaining term of the loan, through its final maturity date of March 1, 2020.

Table of Contents

We incurred issuance costs of $0.2 million, and have accrued an additional $1.2 million for a facility charge which is payable at the earlier of the repayment of the loan in full or the final maturity date. The $1.4 million debt issuance costs will be recognized over the term of the loan as additional interest expense.

We will pay interest on the loan at the greater of either (i) 9.35% plus the prime rate as reported in the Wall Street Journal minus 3.5% and (ii) 9.35%. For additional information about the loan, see Note 5 - Debt to the unaudited financial statements included herein.

C ash Flows

The following table sets forth a summary of our cash flows for the six months ended June 30, 2016 and 2015:



	Six Months Ended June 30,
	2016			2015			Change
	(in thousands)
Net cash used in operating activities	$	(24,550	)	$	(16,151	)	$	(8,399	)
Net cash used in investing activities	(11,409		)	(74,038		)	62,629
Net cash provided by financing activities	15,267			233			15,034
Net change in cash and cash equivalents	$	(20,692	)	$	(89,956	)	$	69,264

Operating Activities

Net cash used in operating activities for the six months ended June 30, 2016 was comprised of a net loss of $31.6 million , which included depreciation expense of $1.0 million and share-based compensation expense of $6.2 million . Net cash used in operating activities was also primarily comprised of the following primary components: a decrease in receivables of $0.1 million , a decrease in prepaid expenses and other assets of $0.3 million and a decrease in accounts payable and other liabilities of $0.8 million .

Net cash used in operating activities for the six months ended June 30, 2015, was comprised of a net loss of $18.3 million , which included depreciation expense of $0.4 million and share-based compensation expense of $3.6 million . Net cash used in operating activities was also primarily comprised of the following primary components: a decrease in receivables of $0.2 million , a decrease in other assets of $0.9 million and a decrease in accounts payable and other liabilities of $0.9 million .

Investing Activities

Net cash used in investing activities for the six months ended June 30, 2016 was $11.4 million , consisting of the purchase of investment securities of $22.7 million , offset by the proceeds from sale of investment securities of $15.9 million and the purchase of property and equipment of $4.6 million . Net cash used in investing activities for the six months ended June 30, 2015 consisted of $74.0 million , consisting of the purchase of investment securities of $73.6 million , offset by proceeds from the sale of investment securities of $2.3 million and purchases of property and equipment of $2.7 million .

Financing Activities

Net cash provided by financing activities for the six months ended June 30, 2016 was $15.3 million , which was derived from borrowings on long-term debt of approximately $15.0 million , payment of debt issuance costs of approximately $0.2 million , proceeds from the exercise of stock options of $0.3 million and proceeds of $0.2 million from employee purchases of common stock under the ESPP. Net cash provided by financing activities for the six months ended June 30, 2015 was $0.2 million , which was derived primarily from proceeds from employee purchases of common stock under the ESPP.

Funding Requirements

Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research and development services, laboratory and related supplies, clinical costs, legal and other regulatory expenses, facility costs and general overhead costs. In addition, we expect to use capital to expand our manufacturing capabilities.

The successful development of any of our product candidates is highly uncertain. As such, at this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the development of BPX-501 or our other current and future product candidates. We are also unable to predict when, if ever, material net cash inflows will commence

Table of Contents

from the sale of product candidates. This is due to the numerous risks and uncertainties associated with developing medical treatments, including, but not limited to, the uncertainty of:


•	successful enrollment in, and successful completion of, clinical trials;


•	receipt of marketing approvals from applicable regulatory authorities;


•	making arrangements with third-party manufacturers;


•	obtaining and maintaining patent and trade secret protection and regulatory exclusivity;


•	launching commercial sales of our products, if and when approved, whether alone or in collaboration with others; and


•	market acceptance of our products, if and when approved.

A change in the outcome of any of these variables with respect to the development of any of our product candidates would significantly change the costs and timing associated with the development of that product candidate.

Because all of our product candidates are in the early stages of clinical and preclinical development and the outcome of these efforts is uncertain, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of product candidates or whether, or when, we may achieve profitability. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity or debt financings and collaboration arrangements.

We plan to continue to fund our operations and capital funding needs through equity and/or debt financing. We may also consider new collaborations or selectively partnering our technology. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our stockholders will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of our existing stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and could involve certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms unfavorable to us. Any of these actions could harm our business, results of operations and future prospects.

Outlook

Based on our research and development plans and our timing expectations related to the progress of our programs, we expect that our cash and cash equivalents as of June 30, 2016 will enable us to fund our operating expenses and capital expenditure requirements through 2017. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Furthermore, our operating plan may change, and we may need additional funds to meet operational needs and capital requirements for product development and commercialization sooner than planned. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates and the extent to which we may enter into additional collaborations with third parties to participate in their development and commercialization, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical trials. Our future funding requirements will depend on many factors, as we:


•	initiate or continue clinical trials of BPX-501, BPX-701 and BPX-601 and any other product candidates;


•	continue the research and development of our product candidates; seek to discover additional product candidates; seek regulatory approvals for our product candidates if they successfully complete clinical trials;

•

establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize any products that may receive regulatory approval; enhance operational, financial and information management systems and hire additional personnel, including personnel to support development of our product candidates and, if a product candidate is approved, our commercialization efforts; and


•	incur additional costs associated with being a public company.

Table of Contents

Contractual Obligations and Commitments

Our contractual obligations as of June 30, 2016 were as follows:



	Commitment		Less Than 1 Year		1 to 3 Years		3 to 5 Years		More Than 5 Years
	(in thousands)
License agreements (1)	$	143,634	$	1,568	$	6,976	$	20,395	$	114,695
Long-term debt obligations (2)	15,000		—		10,128		4,872		—
Operating lease agreements (3)	14,638		1,927		4,052		2,703		5,956
Manufacturing arrangements (4)	3,004		2,274		730		—		—
Sponsored research agreements (5)	2,995		988		2,007		—		—
Preclinical studies (6)	630		630		—		—		—
Capital lease agreements (7)	279		55		109		109		6
Other	453		370		83		—		—
Total contractual obligations	$	180,633	$	7,812	$	24,085	$	28,079	$	120,657

(1)

License agreements - We have entered into several license agreements under which we obtained rights to certain intellectual property. Under the agreements, we could be obligated for payments upon successful completion of clinical and regulatory milestones regarding the products covered by this license. The obligations listed in the table above represent estimates of when the milestones will be achieved. The milestones may not be completed when estimated or at all. See Note 12 to the audited financial statements included in our Annual Report.


(2)	Long-term debt obligations - Obligations under our credit facility. See Note 5 to the unaudited financial statements included herein and Note 15 to the audited financial statements included in our Annual Report.


(3)	Operating lease agreements - The amounts above are comprised of one five-year lease agreement, and one 11-year lease agreement. The first lease will expire on January 31, 2020 and the second lease expires on August 31, 2026. See Note 12 to the audited financial statements included in our Annual Report.


(4)	Manufacturing arrangements - We have entered into a number of manufacturing service arrangements with various terms. The obligations listed in the table above represent estimates of when certain services will be performed.


(5)	Sponsored research agreements - We entered into a number of separate sponsored research agreements to undertake research which is of mutual interest to all parties. The various commitments range from 14 months to three years.


(6)	Preclinical studies - We have entered into a number of preclinical studies with various terms. The obligations listed in the table above represent estimates of when certain services will be performed.


(7)	Capital lease agreements - We have entered into a number of office capital lease agreements with various terms. The commitments include equipment, maintenance and supplies. See Note 12 to the audited financial statements included in our Annual Report.

Recent Accounting Pronouncements

See Note 2 to the Notes to Unaudited Financial Statements in “Item 1 - Financial Statements” in this Quarterly Report for discussion regarding recent accounting pronouncements.

Off-Balance Sheet Arrangements

During the periods presented, we did not have, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the Securities and Exchange Commission.

Table of Contents

Item 3. Quantitative and Qualitative Disclosures about Market Risks

The primary objective of our investment activities is to preserve our capital and meet our liquidity needs to fund operations. We also seek to generate competitive rates of return from our investments without assuming significant risk. To achieve our objectives, we maintain a portfolio of cash equivalents and investments in a variety of securities that are of high credit quality based on ratings from commonly relied upon rating agencies. As of June 30, 2016, we had cash, cash equivalents and investment securities of $136.6 million . Our cash, cash equivalents and investments in investment securities may be subject to interest rate risk and could fall in value if market interest rates increase. However, because our cash is invested in accounts with market interest rates and because our cash equivalents and investments in investment securities are traded in active markets, we believe that our exposure to interest rate risk is not significant and estimate that an immediate and uniform 10% increase in market interest rates from levels as of June 30, 2016 would not have a material impact on the total fair value of our portfolio.

We sometimes contract for the conduct of clinical trials or other research and development and manufacturing activities with contract research organizations, clinical trial sites and contract manufacturers in Europe, and in the future potentially elsewhere outside of the United States. We may be subject to exposure to fluctuations in foreign currency exchange rates in connection with these agreements. If the average exchange rate between the currency of our payment obligations under any of these agreements and the U.S. dollar were to strengthen or weaken by 10% against the corresponding exchange rate as of June 30, 2016, we estimate that the impact on our financial position, results of operations and cash flows would not be material. We do not hedge our foreign currency exposures.

We have not used derivative financial instruments for speculation or trading purposes.

Item 4. Controls and Procedures

Management’s Evaluation of our Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial and Accounting Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of June 30, 2016. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure.

Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of June 30, 2016, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during our latest fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

Our business and results of operations are subject to a number of risks and uncertainties. You should carefully consider the risk factors described under the heading “Risk Factors” in our Annual Report and in other reports we file with the SEC.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Recent Sales of Unregistered Securities

None.

Use of Proceeds from Initial Public Offering of Common Stock

On December 23, 2014, we completed the initial public offering of our common stock pursuant to a registration statement on Form S-1(File Nos. 333-200328 and 333-201031), which was declared effective by the SEC on December 17, 2014.

As of June 30, 2016, we have used the net offering proceeds from our initial public offering to fund operations, capital expenditures, working capital and other general corporate purposes and for debt repayment. We are holding the balance of the net proceeds from the offering in cash, cash equivalents and investment securities. There has been no material change in our planned use of the balance of the net proceeds from the offering described in our final prospectus filed with the SEC on December 17, 2014 pursuant to Rule 424(b) under the Securities Act.

Purchase of Equity Securities

We did not purchase any of our registered securities during the period covered by this Quarterly Report.

Item 6. Exhibits

The exhibits filed as part of this Quarterly Report are set forth on the Exhibit Index, which is incorporated herein by reference.

Table of Contents

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



	Bellicum Pharmaceuticals, Inc.

Date: August 8, 2016	By:	/s/ Thomas J. Farrell
		Thomas J. Farrell
		President and Chief Executive Officer

Date: August 8, 2016	By:	/s/ Alan A. Musso
		Alan A. Musso
		Chief Financial Officer and Treasurer Principal Financial and Accounting Officer

Table of Contents



EXHIBIT INDEX
Exhibit number		Description of exhibit

3.1(1)		Amended and Restated Certificate of Incorporation of the Registrant.

3.2(1)		Amended and Restated Bylaws of the Registrant.

4.1		Reference is made to Exhibits 3.1 and 3.2.

4.2(2)		Form of Common Stock Certificate of the Registrant.

4.3(2)		Second Amended and Restated Investor Rights Agreement by and among the Registrant and certain of its stockholders, dated August 22, 2014.

4.4(3)		Registration Rights Agreement by and among the Registrant and Baker Brothers Life Sciences, LP, and two of its affiliated funds, dated January 15, 2016.

10.1+		Consulting Agreement, by and between the Registrant and Kevin M. Slawin, M.D., dated May 18, 2016.

10.2*		Sponsored Research Agreement No. 2, by and between the Registrant and Academish Ziekenhuis Leiden, also acting under the name Leiden University Medical Centre, dated May 20, 2016.

10.3		First Amendment to Lease Agreement, by and between the Registrant and Life Science Plaza Investment Group, LP, as successor-in-interest to Sheridan Hills Developments, L.P., dated July 11, 2016.

31.1		Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2		Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1		Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Instance Document

101.SCH		XBRL Taxonomy Extension Schema Document

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document

101.LAB		XBRL Taxonomy Extension Label Linkbase Document

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

(1)		Incorporated by reference to the Registrant's Current Report on Form 8-K, filed with the SEC on December 23, 2014.

(2)		Incorporated by reference to the Registrant's Registration Statement on Form S-1 (File No. 333-200328), as amended, originally filed with the SEC on November 18, 2014.

(3)		Incorporated by reference to the Registrant's Annual Report on Form 10-K, filed with the SEC on March 14, 2016.

+		Indicates management contract or compensatory plan.

*		Confidential treatment has been granted with respect to certain portions of this exhibit. Omitted portions have been filed separately with the SEC.



Upfront fee	No upfront fee shall be due
Payments
Royalties on Net Sales	Licensee shall pay to LUMC a royalty rate of […***…]% on Net Sales (see definition below).
Annual license maintenance fee	As of the 8 ^th anniversary of the effective date of the first license agreement, Licensee will begin paying an annual license maintenance fee of €30.000. As of the 8 ^th anniversary of the effective date of any additional license agreement(s), Licensee will begin paying a supplementary annual license maintenance fee of €10.000 for each such additional license agreement then in effect.
Sublicense Income	a) […*…]% of Sublicense Income received for Sublicense Agreements entered into [……]; b) [……]% of Sublicense Income for Sublicense Agreements entered into [……]; c) [……]% of Sublicense Income for Sublicense Agreements entered into […*…] (See definition of Sublicense Income below).
Milestone payments	For each TCR selected for Bellicum development: […*…]: [……] euro [……]: [……] euro [……]: [……] euro Milestone payments apply only once for a given TCR specificity, regardless of the number of HLA restricted TCRs and licensed products (“Licensed Products”) that are developed for that specificity. So for example, a Licensed Product based on [……] might go all the way through approval and trigger each of the milestone payments, but a Licensed Product based on […*…] would not trigger additional milestone payments. A TCR with specificity directed to a different antigen (and related Licensed Products) would trigger its own one-time only milestone payments.



Performance & license obligations
Patent obligations	Licencee will insure that appropriate IP is secured on behalf of LUMC for inventions directed to a TCR that is the subject of a Research Program and for which a licence agreement is executed, as such TCR(s) is/are agreed within […***…] of the signing of said license agreement (for each such TCR, this IP is the “TCR IP”). Licensee will be obliged to diligently file and prosecute such applications on behalf of LUMC, with the objective of obtaining optimal commercially reasonable coverage for each such TCR IP. All patent expenses incurred in acquition of TCR IP rights, including filing and prosecution expenses, will be borne by Licensee. Should Licensee later elect not to pursue said TCR IP, all rights, including TCR IP prosecution rights, will revert to LUMC.
Performance obligations	Realistic performance obligations regarding each such TCR (and related Licensed Products) for which a license agreement is executed shall be agreed between Licensee and LUMC at time of signing such licence agreement. Should Licensee fail to meet such agreed performance obligations (as these may be amended or extended) regarding any such TCR (and related Licensed Products), all rights regarding such TCR (and related Licensed Products), including TCR IP prosecution rights, will revert to LUMC.



Months following the Commencement Date	Annual Rate/SF	Annual Base Rent	Monthly Installments
61-72	$36.50	$923,596.00	$79,966.33
73 - 84	$37.80	$956,491.20	$79,707.60



85 - 96	$39.10	$989,386.40	$82,448.87
97 - 108	$40.50	$1,024,812.00	$85,401.00
109 - 120	$41.90	$1,060,237.60	$88,353.13
121- 132	$43.35	$1,096,888.00	$91,407.33



Months following the Commencement Date	Annual Rate/SF	Annual Base Rent	Monthly Installments
61 - 72	$26.50	$18,682.50	$1,556.88
73 - 84	$27.80	$19,599.00	$1,633.25
85 - 96	$29.10	$20,515.50	$1,709.63
97 -108	$30.50	$21,502.50	$1,791.88
109 - 120	$31.90	$22,489.50	$1,874.13
121 - 132	$33.35	$23,512.00	$1,959.33


•	Establish a regular schedule of Science Committee meetings and work with the Science Committee chairman and senior management to identify and prioritize key agenda items and ensure follow-up and closure.


•	Interface with the R&D leadership and participate in activities and meetings as requested by the Company’s Chief Scientific Officer.


A.	Should Leiden materially breach this Agreement or become unable to perform hereunder, Sponsor shall have the right to terminate this Agreement. Sponsor shall notify Leiden in writing of its intention to terminate, and termination shall become effective thirty (30) days thereafter if, during such thirty (30) day period, Leiden is unable to cure the breach or rectify its performance.


B.	Material breach of this Agreement by Sponsor and failure of Sponsor to pay any undisputed amount owed hereunder within thirty (30) days after receipt of an invoice from Leiden shall be cause for Leiden to terminate


b)	not communicate, disclose or otherwise make available such information to any third party (not including sublicensees) except with prior, written and explicit consent from the Disclosing Party;


c)	communicate, disclose or otherwise make available such information to members of its personnel and sublicensees only and strictly on a “need-to-know” basis, that is, only in so far as disclosure to a particular individual is strictly necessary for the purpose of this


d)	not use such information other than for the purpose for which the information was disclosed;


e)	take all reasonable steps to ensure that such information shall be protected against unauthorized access, theft, and the like.


C.	The obligations as set out in Article 7.B shall not apply or shall cease to apply, to information of which the Receiving Party can demonstrate by (documentary) evidence:


a)	that it was in the public domain prior to the disclosure under this Agreement;


b)	that it was in the Receiving Party’s possession prior to the disclosure under this Agreement, provided it was not acquired by the Receiving Party under confidentiality obligations directly or indirectly from the Disclosing Party;


c)	that, after its disclosure under this Agreement, it became part of the public domain through no act or omission of the Receiving Party;


e)	that it is required under a statutory duty and/or court order to disclose, provided that advance written notice is given to the Disclosing Party and the Receiving Party takes all reasonable measures to protect the confidentiality of the information and to cooperate with the Disclosing Party’s efforts, at its expense, to avoid or limit disclosure.


D.	Upon termination or expiry of this Agreement, each Receiving Party will at the first request of the Disclosing Party destroy any and all of the Disclosing Party’s Confidential Information.


E.	Leiden shall provide to Sponsor a complete written disclosure for each and every Sole Leiden Invention and Joint Invention, whether or not patentable, first conceived or reduced to practice in the performance of the Research funded under this Agreement, promptly after each such Sole Leiden Invention and Joint Invention is made.


F.	Any data, information, results, technology, know-how, and trade secrets generated, developed, derived or otherwise obtained in the performance of the Research Program, to the extent the foregoing do not constitute a Sole Leiden


G.	It is anticipated that the form and terms of any license agreement entered into by the Parties pursuant to Section 9.D would be based on a form and terms similar to those set forth in the License Agreement and in Appendix C .


I.	Each Party makes no representation or warranty that any act or any manufacture that uses information from the Research Program, including any Project Invention and/or any Research Program IP, (whether under a license under this Article 9 or otherwise) will be free from infringement of patents of third parties or other rights of third parties.


A.	Leiden shall not knowingly incorporate in any deliverable under this Agreement any intellectual property rights of any third party.


(a)	The Manufacturing Space Base Rent for months 61 -132 shall be:


(b)	The Interior Mechanical Space Base Rent for months 61 through 132 shall


(c)	The Exterior Mechanical Space Base Rent for months 61 through 132 shall



Period	Annual Rate/SF	Annual Base Rent	Monthly Installments
Expansion Date -August 31, 2016	$20.75	$69,056.00	$5,754.67
September 1, 2016 -August 31, 2017	$21.80	$72,550.00	$6,045.83
September 1, 2017 -August 31, 2018	$22.95	$76,378.00	$6,364.83
September 1, 2018 -August 31, 2019	$24.10	$80,205.00	$6,683.75
September 1, 2019 -August 31, 2020	$25.30	$84,198.00	$7,016.50
September 1, 2020 -August 31, 2021	$26.50	$88,192.00	$7,349.33
September 1, 2021 -August 31, 2022	$27.80	$92,518.00	$7,709.83
September 1, 2022 -August 31, 2023	$29.10	$96,845.00	$8,070.42
September 1, 2023 -August 31, 2024	$30.50	$101,504.00	$8,458.67
September 1, 2024 -August 31, 2025	$31.90	$106,163.00	$8,846.92
September 1, 2025 -August 31, 2026	$33.35	$110,989.00	$9,249.08


(i)	The Manufacturing Space Base Rent for the Extended Term shall be:



Months following the commencement of the Extended Term	Annual Rate/SF	Annual Base Rent	Monthly Installments
1- 12	$44.65	$1,129,794.00	$94,149.50
13 - 24	$45.99	$1,163,688.00	$96,974.00
25 - 36	$47.37	$1,198,599.00	$99,883.25
37 - 48	$48.79	$1,234,557.00	$102,879.75
49 - 60	$50.25	$1,217,594.00	$105,966.17


(ii)	The Interior Mechanical Space Base Rent for the Extended Term



37 - 48	$38.79	$27,346.00	$2,278.83
49 - 60	$40.25	$28,378.00	$2,364.83


(iii)	The Expansion Space Base Rent for the Extended Term shall be:


(iv)	The Exterior Mechanical Space Base Rent for the Extended Term


12.	Services and Utilities to Manufacturing Space and Expansion Space .